Laboratory Methods for Monitoring Influenza Antiviral Resistance
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Emi Takashita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Resistance, Viral, Influenza, Human, Orthomyxoviridae. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 120 Literaturangaben.
Abstract (Originalsprache)
Monitoring antiviral susceptibility is an essential component of virologic surveillance conducted by laboratories participating in the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS). Since 2011, the WHO Expert Working Group on Surveillance of Influenza Antiviral Susceptibility (WHO-AVWG) has annually published recommendations for assessing antiviral susceptibility of circulating viruses. This approach includes (i) screening viral RNA sequences for amino acid substitutions (molecular markers) known or suspected to confer reduced susceptibility, and (ii) testing viruses for antiviral susceptibility. Recently, next-generation sequencing of the whole viral genome has been implemented in many reference laboratories and could be used to test clinical specimens. Susceptibility to neuraminidase inhibitors (NAIs) is analyzed using neuraminidase activity-based assays with small synthetic substrates, while susceptibility to baloxavir is determined using replication-based assays. Since laboratory correlates of clinically significant antiviral resistance are not yet established, interpretation of antiviral testing outcomes follows the arbitrary WHO-AVWG criteria, where 50% inhibitory/effective concentration (IC50/EC50) values are compared to a virus type-, subtype-, or lineage-specific median to determine a fold change. For NAIs, the level of the enzyme's inhibition is reported as normal (<10-fold; <5-fold), reduced (10- to 100-fold; 5- to 50-fold), or highly reduced (>100-fold; >50-fold) for types A and B, respectively. For baloxavir, reduced susceptibility is provisionally defined as >3-fold above the median EC50. Additional considerations including preclinical testing in animal models may shed further light on antiviral susceptibility related to drug exposures relevant to humans and the fitness of viruses that contain reduced drug susceptibility genotypes. This framework provides a harmonized approach for monitoring antiviral susceptibility of influenza viruses needed to inform public health responses and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Emi Takashita, Jeremy C Jones
Zitieren
APA
Takashita, E., Wolfe, C. R., & Jones, J. C. (2025). Laboratory Methods for Monitoring Influenza Antiviral Resistance. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf299
Vancouver
Takashita E, Wolfe CR, Jones JC. Laboratory Methods for Monitoring Influenza Antiviral Resistance. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf299
BibTeX
@article{Takashita2025,
author = {Takashita, Emi and Wolfe, Cameron R and Jones, Jeremy C},
title = {Laboratory Methods for Monitoring Influenza Antiviral Resistance},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf299}
}
EUVIMED